Latest News in the pharma Industry

Research & Development

Ixekizumab demonstrates rapid, improvements as among patients with moderate-to-severe plaque psoriasis

Ixekizumab demonstrates rapid, improvements as among patients with moderate-to-severe plaque psoriasis

6 Mar 2016

In a combined analysis of UNCOVER-2 and UNCOVER-3, significant improvement of psoriasis plaques was observed in patients treated with ixekizumab at 1, 2 and 4 weeks.

Read more 
Onconova Therapeutics receives notice of termination for convenience from Baxalta

Onconova Therapeutics receives notice of termination for convenience from Baxalta

4 Mar 2016

Rights to commercialize rigosertib in Europe to revert to Onconova.

Read more 
FDA approves new indication for Faslodex (fulvestrant)

FDA approves new indication for Faslodex (fulvestrant)

3 Mar 2016

Approval expands use and offers additional option for women with HR+, HER2- metastatic breast cancer.

Read more 
Breast cancer is only pharmaceutical pipeline with over 1000 drugs in development

Breast cancer is only pharmaceutical pipeline with over 1000 drugs in development

3 Mar 2016

GBI Research says the pipeline may significantly alter the clinical and commercial landscape of the disease market over the next decade.

Read more 
Merck initiates Phase III study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis

Merck initiates Phase III study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis

2 Mar 2016

Study will evaluate efficacy, safety and immunogenicity of adalimumab biosimilar candidate MSB11022 compared with Humira.

Read more 
Concert Pharmaceuticals announces CTP-656 solid dose Phase I results confirmed superior pharmacokinetic profile to Kalydeco

Concert Pharmaceuticals announces CTP-656 solid dose Phase I results confirmed superior pharmacokinetic profile to Kalydeco

2 Mar 2016

Concert is using this tablet formulation of CTP-656 in its ongoing multiple ascending dose Phase I clinical trial and intends to use the same formulation in a Phase II clinical trial.

Read more 
Sobi and Biogen receive positive opinion from CHMP for Alprolix (rFIXFc) for the treatment of hemophilia B

Sobi and Biogen receive positive opinion from CHMP for Alprolix (rFIXFc) for the treatment of hemophilia B

2 Mar 2016

If approved, Alprolix would be among the first therapies in the European Union (EU) to offer people living with hemophilia B prolonged protection against bleeding episodes with prophylactic dosing intervals.

Read more 
Acticor Biotech selects Catalent GPEx Cell Line Development Technology to develop ACT-017

Acticor Biotech selects Catalent GPEx Cell Line Development Technology to develop ACT-017

1 Mar 2016

Acticor Biotech is developing an antibody fragment (Fab) considered as a first-in-class anti-thrombotic agent without bleeding risk in the primary treatment of ischemic strokes.

Read more 
Company pioneering nanotechnology to bring innovative medicines that make a real difference

Company pioneering nanotechnology to bring innovative medicines that make a real difference

1 Mar 2016

Blueberry Therapeutics is set to create safe, effective “nanomedicines” to treat a number of unmet clinical needs.

Read more 
Chem-Space launches to provide largest global chemical database and search tool

Chem-Space launches to provide largest global chemical database and search tool

1 Mar 2016

Chem-space.com online searchable marketplace features over 15 million compounds.

Read more 
Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss

Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss

29 Feb 2016

NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild.

Read more 
True North Therapeutics receives Orphan Drug Designation in the EU for TNT009 for the treatment of autoimmune hemolytic anemia, including CAD

True North Therapeutics receives Orphan Drug Designation in the EU for TNT009 for the treatment of autoimmune hemolytic anemia, including CAD

29 Feb 2016

Top-line Phase Ib data in patients with CAD expected in mid-2016.

Read more